Literature DB >> 20218011

Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations.

J G Wagner1, R G Stoll, D J Weidler, J W Ayres, M R Hallmark, E Sakmar, A Yacobi.   

Abstract

A blinded, four-treatment crossover study in 16 normal adult male volunteers compared plasma concentrations and urinary excretion of digoxin, measured by radioimmunoassay, after oral administration of soft gelatin capsule formulations of digoxin. Four 0.4-mg formulations with different in vitro "burst times" and dissolution rates were administered, with 2-week intervals between treatments. The two capsules with lowest in vitro burst times (2.9 and 16 min) gave comparable in vivo results. The other two capsules, with in vitro burst times of 62 and 229 min, produced significant delays in digoxin absorption. In vitro-in vivo correlations were obtained by comparing the logarithm of the in vitro burst time with time to peak plasma level and the time to the first measurable plasma level (> or = 0. 05 ng/ml). Also, the mean time to peak plasma level correlated with the logarithm of the time required to release either 50% or 85% of the digoxin in vitro. No significant changes were found in the amount of digoxin absorbed from each capsule as determined by urinary excretion or AUC0-infinity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 20218011     DOI: 10.1007/bf01059735

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  11 in total

1.  Spectrofluorometric analysis of cardiotonic steroids.

Authors:  D WELLS; B KATZUNG; F H MEYERS
Journal:  J Pharm Pharmacol       Date:  1961-07       Impact factor: 3.765

2.  Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin.

Authors:  J G Wagner; J W Ayres
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Sensitive radioimmunoassay for digoxin in plasma and urine.

Authors:  J G Wagner; M R Hallmark; E Sakmar; J W Ayres
Journal:  Steroids       Date:  1977-06       Impact factor: 2.668

4.  Novel method for bioavailability assessment.

Authors:  K C Kwan; A E Till
Journal:  J Pharm Sci       Date:  1973-09       Impact factor: 3.534

5.  Greater bioavailability of digoxin solution in capsules. Studies in the postprandial state.

Authors:  J Lindenbaum
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

6.  Superior bioavailability of digoxin solution in capsules.

Authors:  G I Mallis; D H Schmidt; J Lindenbaum
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

7.  Drug bioavailability studies.

Authors:  J G Wagner
Journal:  Hosp Pract       Date:  1977-01

8.  The assessment of the intrasubject variability in digoxin absorption in man from two oral dosage forms.

Authors:  A Yacobi; R G Stoll; G C Chao; R A Schwartz; D J Weidler; J W Ayers; E Sakmar; M Hallmark; J G Wagner
Journal:  J Clin Pharmacol       Date:  1981-07       Impact factor: 3.126

9.  The comparability of dosage regimens of Lanoxin tablets and Lanoxicaps.

Authors:  B F Johnson; G Smith; J French
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

10.  A completely absorbed oral preparation of digoxin.

Authors:  B F Johnson; C Bye; G Jones; G A Sabey
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

View more
  2 in total

1.  Evidence of nonlinearity in digoxin pharmacokinetics.

Authors:  J G Wagner; K D Popat; S K Das; E Sakmar; H Movahhed
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

2.  Absorption of digoxin from a new microencapsulated formulation.

Authors:  B Bergdahl; C Bogentoft; U E Jonsson; J O Magnusson
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.